Last reviewed · How we verify
Clemastin
At a glance
| Generic name | Clemastin |
|---|---|
| Sponsor | Technical University of Munich |
| Target | 5-hydroxytryptamine receptor 6, Cytochrome P450 2C19, Solute carrier family 22 member 1 |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Approved indications
- Allergic conjunctivitis
- Allergic rhinitis
- Anaphylaxis Adjunct
- Dermatographic urticaria
- Itching of skin
- Nasal congestion
- Nasal discharge
- Sneezing
- Urticaria
- Vasomotor rhinitis
Common side effects
Key clinical trials
- Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema (PHASE3)
- The Effect of Histamine H1 Receptor Antagonist, Clemastin, on PACAP38 Induced Headache in Migraine Patients (NA)
- AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |